Elsevier 2023 SDG mapping
Tips
How to read a Scopus query
The Scopus queries presented in this view correspond to what is known on scopus.com as advanced search queries. Advanced searches allow a query creator to create complex and robust queries using field codes, Boolean operators, or proximity operators. We detail each of these elements below.
Field codes
A typical publication's Scopus record contains a myriad of information about it. To make this information easily usable, this information is structured and parsed apart in different fields, each containing a given type of information. For example, the title field contains a publication's title, and the publication year field informs us about when a given publication was first made public.
Field codes are there to indicate which field(s) we would like to source information from when conducting a given search. To avoid searches becoming overly long, they are usually shortened words such as ABS, which stands for "Abstract". The most commonly-used field codes used by our query-building team are:
- TITLE-ABS-KEY
Searches through the Title, Abstract, and all Keywords - TITLE-ABS
Searches only through the Title and Abstract - AUTHKEY
Searches only through the Author-defined keywords - SRCTITLE
Searches only through the journal or conference proceedings' titles
To conduct a search in a given field, the syntax is always field-code(search-term).
The field codes used can potentially have a deep impact on a search. For example, searching for "Canada" in field AFFILCOUNTRY would return publications where at least one author was affiliated with a Canadian institution, while the same search conducted in field TITLE-ABS-KEY would return articles that concern Canada.
Boolean operators
In most cases, conducting a Scopus search using a single field code or a single term is not sufficient to obtain a robust set of results. To remedy this, Scopus searches make use of boolean operators to allow for the combination of different terms or query parts. The allowed operators are
- OR
At least one of the terms must appear in the specified field, or at least one of the searches must match - AND
Both of the terms must appear in the specified field, or both searches must match - AND NOT
Only the first term must appear in the specified field, or only the first search must match
Boolean operators are applied in the order they were listed above. Therefore, KEY(mouse AND NOT cat OR dog) is interpreted as KEY((mouse) AND NOT (cat OR dog)).
Proximity operators
In some instances, a certain word is deemed relevant to a topic only if it is close to another word in the text, or certain phrasings might space out two related words defining a topic, which we could want to be tolerant to. For example, the sentence "publishing scholarly journals" is relevant to the topic of "scholarly publishing", but searching for "scholarly publishing" alone would not capture an article that used this expression.
Using proximity searches enable building queries that are tolerant to such things. Two proximity search operators are available in Scopus:
- W/n
Both terms must be within n words of each other, but not in any particular order - PRE/n
Both terms must be within n words of each other, in the order they are listed in
For example, the search TITLE-ABS-KEY("journal" W/2 "publishing") would capture the sentence from the example above, but TITLE-ABS-KEY("journal" PRE/2 "publishing") would not, since the words are not in the same order.
Introduction
The United Nations Sustainable Development Goals (SDGs) challenge the global community to build a world where no one is left behind.
Since 2018, Elsevier has generated SDG search queries to help researchers and institutions track and demonstrate progress toward the SDG targets. In the past 3 years, these queries, along with the university’s own data and evidence supporting progress and contributions to the particular SDG outside of research-based metrics, are used for the THE Impact Rankings.
Method
For 2023, the SDGs use the exact same search query and ML algorithm as the Elsevier 2022 SDG mappings, with only minor modifications to five SDGs, namely SDG 1, 4, 5, 7 and 14. In these cases, the queries were shortened by removing exclusion lists based on journal identifiers. These exclusion lists often contained thousands of items to filter out content in journals that were not core to the SDGs.
To replicate the effect of these journal exclusions, sets of keywords were used to closely mimic the effects the journal exclusions had on the SDG content, while greatly reducing the overall query size and complexity. By following this approach, we were able to limit the changes to the publications in each SDG by less than 2 percent for most SDGs, while reducing the query size by 50 percent or more.
These shortened queries also have the added benefit of running faster in Scopus, allowing further analysis of the SDG data to be done more easily. Full details of the 2022 methodology are available on Digital Commons Data.
SDG 3 – Good Health and Well-being
Query
Below is the full search query used for SDG 3 – Good Health and Well-being. We’ve broken it down by each query component. Use the + and – buttons to expand or concatenate the different bracket levels.
Subfields of science
In this section, we show how the publication set, captured by the query above, relates to the Science-Metrix classification system.As shown in Figure 1, the publications related to this publication set fall mainly under the subfields of Oncology & Carcinogenesis (1,009,079 publications), Cardiovascular System & Hematology (486,921 publications) and General & Internal Medicine (441,571 publications). The total share of each subfield included under the publication set are presented upon hovering your cursor over the bars.
Journals
In this section, we show how the publication set, captured by the query above, relates to scholarly journals. Journals are sorted in terms of their total output in the field. The horizontal bars are proportional to the number of publications contributed by the journal to the current publication set. To see the proportion of the total publications in the journal contributing to this publication set or their relevance score, you can hover your cursor over the bars.The articles on this topic are published most frequently in the following journals: PLoS ONE (98,523 publications), Scientific Reports (43,239 publications) and Journal of Biological Chemistry (34,975 publications).
Keywords
Elsevier’s Scopus database of scientific literature, was used for the table below. The document types included in the data sets are journal articles, reviews, short surveys and conference papers, covering the period 1996–2022. We refer to these documents collectively as “publications” or “papers”.In order to help better illustrate the content of this set of publications, indicators associated with the keywords most specific to this set (according to a TF-IDF score) are presented below.
Term | Papers with this term in the publication set | Papers with this term in all of Scopus | Relevance (tf-idf) | Percentage of Scopus |
---|---|---|---|---|
national institutes of health stroke scale score | 1802 | 1820 | 19.061722 | 99 |
international association for the study of lung cancer | 2263 | 2318 | 19.047408 | 98 |
stroke thrombectomy | 1715 | 1745 | 19.042849 | 98 |
functional assessment of cancer therapy | 2793 | 2864 | 19.038718 | 98 |
european prospective investigation into cancer | 1617 | 1643 | 19.038015 | 98 |
sustained virological response (svr) | 2512 | 2585 | 19.037375 | 97 |
alcohol use disorders identification test | 2409 | 2481 | 19.036849 | 97 |
diabetes mellitus, type 2 | 1543 | 1565 | 19.034461 | 99 |
breast cancer resistance protein | 2388 | 2468 | 19.030318 | 97 |
adolescents with type 1 diabetes | 2576 | 2665 | 19.026263 | 97 |
national cancer database | 3669 | 3725 | 19.024994 | 98 |
hiv/hcv | 2128 | 2205 | 19.024503 | 97 |
kaposi's sarcoma-associated herpesvirus | 2098 | 2176 | 19.022248 | 96 |
barcelona clinic liver cancer | 1775 | 1830 | 19.022243 | 97 |
european prospective investigation into cancer and nutrition | 1439 | 1461 | 19.020913 | 98 |
distant metastasis-free survival | 2283 | 2374 | 19.018936 | 96 |
breast cancer resistance | 2619 | 2720 | 19.018079 | 96 |
oropharyngeal squamous cell carcinoma | 2566 | 2667 | 19.017540 | 96 |
mda-mb-231 breast cancer cells | 2054 | 2135 | 19.017358 | 96 |
metastatic renal cell carcinoma (mrcc) | 1797 | 1859 | 19.017141 | 97 |
european organisation for research and treatment of cancer | 1831 | 1896 | 19.017042 | 97 |
incident diabetes | 1995 | 2073 | 19.016575 | 96 |
high-risk prostate cancer | 1867 | 1936 | 19.016040 | 96 |
plasma hiv-1 rna | 1437 | 1463 | 19.015680 | 98 |
biochemical failure | 2170 | 2260 | 19.015415 | 96 |
metastatic colorectal cancer (mcrc) | 3188 | 3289 | 19.014095 | 97 |
pathologic complete response (pcr) | 1647 | 1698 | 19.013829 | 97 |
national institutes of health stroke scale (nihss) | 3233 | 3333 | 19.013770 | 97 |
chemoradiotherapy (crt) | 2986 | 3093 | 19.013482 | 97 |
national institute of health stroke scale | 1833 | 1902 | 19.013308 | 96 |
prostate-specific membrane antigen (psma) | 2024 | 2108 | 19.012982 | 96 |
metastatic castration-resistant prostate cancer (mcrpc) | 1633 | 1685 | 19.011174 | 97 |
pandemic influenza a | 2100 | 2191 | 19.011174 | 96 |
colorectal cancer (crc) screening | 1698 | 1757 | 19.010802 | 97 |
mda-mb-231 breast cancer cell | 2626 | 2739 | 19.009708 | 96 |
chronic hepatitis c (chc) | 2512 | 2624 | 19.008761 | 96 |
metastatic crc | 1922 | 2004 | 19.007955 | 96 |
health services accessibility | 1929 | 2012 | 19.007546 | 96 |
non–small cell lung | 1979 | 2066 | 19.007421 | 96 |
pandemic h1n1 | 1809 | 1882 | 19.007325 | 96 |
hbv genotype | 2169 | 2269 | 19.007052 | 96 |
non–small cell | 2002 | 2093 | 19.005366 | 96 |
cancer and nutrition | 1556 | 1605 | 19.005072 | 97 |
sentinel lymph node biopsy (slnb) | 2140 | 2241 | 19.004781 | 95 |
disease-specific survival (dss) | 2757 | 2879 | 19.004518 | 96 |
2009 pandemic | 2024 | 2118 | 19.004131 | 96 |
substance-related disorder | 2262 | 2371 | 19.003815 | 95 |
asthma control test | 1750 | 1821 | 19.003750 | 96 |
hcc recurrence | 1900 | 1985 | 19.003472 | 96 |
international prognostic index | 2930 | 3054 | 19.003164 | 96 |
substance-related disorders | 2106 | 2207 | 19.002962 | 95 |
mcrpc | 2717 | 2841 | 19.002939 | 96 |
non–small cell lung cancer | 1873 | 1957 | 19.002225 | 96 |
a549 lung cancer | 1800 | 1878 | 19.001587 | 96 |
tumor-node-metastasis | 2424 | 2543 | 19.001561 | 95 |
her2 status | 2540 | 2663 | 19.001335 | 95 |
sln biopsy | 1471 | 1513 | 19.001307 | 97 |
stroke center | 2593 | 2718 | 19.000837 | 95 |
global initiative for chronic obstructive lung disease | 1696 | 1766 | 18.999117 | 96 |
hcv treatment | 3115 | 3245 | 18.997903 | 96 |
non-muscle-invasive | 1833 | 1918 | 18.997798 | 96 |
advanced hepatocellular carcinoma (hcc) | 1781 | 1861 | 18.997794 | 96 |
hcv genotype 1 | 2740 | 2873 | 18.997042 | 95 |
neuroblastoma sh-sy5y cell | 1829 | 1915 | 18.996468 | 96 |
nsclcs | 2218 | 2334 | 18.996270 | 95 |
hiv-uninfected | 3292 | 3421 | 18.995757 | 96 |
cancer cell apoptosis | 2425 | 2552 | 18.995609 | 95 |
hiv-1 subtype | 3245 | 3376 | 18.995439 | 96 |
peripheral artery disease (pad) | 2802 | 2938 | 18.995428 | 95 |
pdm09 | 2289 | 2410 | 18.995414 | 95 |
adults with type 2 diabetes | 3260 | 3391 | 18.995183 | 96 |
metastatic breast cancer (mbc) | 2617 | 2751 | 18.994907 | 95 |
epidermal growth factor receptor (egfr) mutation | 2137 | 2250 | 18.994571 | 95 |
cancer-specific mortality | 3264 | 3396 | 18.994536 | 96 |
papillary thyroid cancer (ptc) | 2024 | 2129 | 18.994444 | 95 |
weekly paclitaxel | 1585 | 1647 | 18.994312 | 96 |
neuroblastoma sh-sy5y | 2012 | 2117 | 18.993617 | 95 |
egfr tyrosine kinase inhibitors | 1922 | 2020 | 18.993160 | 95 |
shiga toxin-producing escherichia coli | 2557 | 2692 | 18.993098 | 95 |
uncontrolled asthma | 1899 | 1996 | 18.992188 | 95 |
prostate cancer radiotherapy | 1717 | 1796 | 18.992145 | 96 |
diabetes status | 2912 | 3055 | 18.991144 | 95 |
opscc | 1469 | 1520 | 18.990259 | 97 |
european society for medical oncology | 3694 | 3816 | 18.989410 | 97 |
neuroblastoma sh-sy5y cells | 1604 | 1673 | 18.989111 | 96 |
baseline hba1c | 1663 | 1739 | 18.989025 | 96 |
asthma outcome | 1476 | 1529 | 18.988979 | 97 |
a549 lung cancer cell | 1611 | 1681 | 18.988935 | 96 |
neoadjuvant chemoradiation | 2054 | 2168 | 18.988630 | 95 |
substance use treatment | 1991 | 2100 | 18.988560 | 95 |
chronic hepatitis c virus (hcv) infection | 2586 | 2729 | 18.988043 | 95 |
cancer-related fatigue | 1715 | 1798 | 18.987828 | 95 |
hbv dna level | 2409 | 2546 | 18.987634 | 95 |
stroke thrombolysis | 1490 | 1546 | 18.987613 | 96 |
head and neck cancer (hnc) | 3078 | 3226 | 18.987410 | 95 |
nmibc | 2285 | 2416 | 18.987398 | 95 |
acute ischemic stroke patients | 2766 | 2914 | 18.987265 | 95 |
diabetes medication | 2084 | 2202 | 18.987170 | 95 |
hiv-rna | 1457 | 1509 | 18.987158 | 97 |
anthracycline-based | 2096 | 2215 | 18.987086 | 95 |
a(h1n1)pdm09 | 1391 | 1434 | 18.987079 | 97 |
follicular lymphoma (fl) | 2162 | 2286 | 18.986846 | 95 |
neoadjuvant chemotherapy (nac) | 3008 | 3158 | 18.986578 | 95 |
anaplastic lymphoma kinase (alk) | 3238 | 3385 | 18.986275 | 96 |
crc risk | 2166 | 2291 | 18.986249 | 95 |
interferon and ribavirin | 2755 | 2905 | 18.985832 | 95 |
trail-induced apoptosis | 1770 | 1861 | 18.985769 | 95 |
cancer stem-like cells | 1889 | 1992 | 18.985735 | 95 |
tuberculin skin test (tst) | 1797 | 1891 | 18.985605 | 95 |
cancer stem-like | 2353 | 2490 | 18.985596 | 94 |
cancer stem-like cell | 2098 | 2219 | 18.985519 | 95 |
clear cell rcc | 1758 | 1848 | 18.985488 | 95 |
childhood cancer survivors | 2471 | 2614 | 18.985169 | 95 |
exposure to pm2.5 | 2051 | 2169 | 18.984972 | 95 |
egfr tk | 1758 | 1849 | 18.984491 | 95 |
asthma phenotype | 1709 | 1795 | 18.984072 | 95 |
slnb | 2728 | 2881 | 18.983525 | 95 |
marginal zone lymphoma | 2415 | 2558 | 18.983365 | 94 |
msi-h | 2347 | 2487 | 18.983068 | 94 |
pediatric obesity | 2384 | 2526 | 18.982994 | 94 |
mantle cell lymphoma (mcl) | 2344 | 2484 | 18.982946 | 94 |
differentiated thyroid cancer (dtc) | 1690 | 1775 | 18.982869 | 95 |
risk of ischemic stroke | 2533 | 2682 | 18.982568 | 94 |
sustained virologic response (svr) | 1491 | 1552 | 18.981918 | 96 |
metastatic nsclc | 1908 | 2017 | 18.981846 | 95 |
concurrent chemoradiation | 2105 | 2231 | 18.981748 | 94 |
egfr tki | 1645 | 1726 | 18.981502 | 95 |
shiga toxin-producing escherichia coli (stec) | 1619 | 1697 | 18.981327 | 95 |
stroke outcomes | 1640 | 1721 | 18.980860 | 95 |
and end results database | 2312 | 2453 | 18.980815 | 94 |
ca-mrsa | 1850 | 1955 | 18.980255 | 95 |
sustained virologic response | 3706 | 3845 | 18.980243 | 96 |
metastatic castration-resistant prostate cancer | 3249 | 3407 | 18.979782 | 95 |
health services access | 2126 | 2256 | 18.979733 | 94 |
asthma outcomes | 1317 | 1355 | 18.979665 | 97 |
latent tuberculosis infection (ltbi) | 1535 | 1604 | 18.979451 | 96 |
pharyngeal squamous cell carcinoma | 3342 | 3499 | 18.978992 | 96 |
hiv-infected adults | 2734 | 2894 | 18.978933 | 94 |
ckd stages | 2179 | 2314 | 18.978808 | 94 |
egfr-tkis | 2454 | 2605 | 18.978787 | 94 |
surveillance, epidemiology, and end results database | 1747 | 1843 | 18.978288 | 95 |
cvd events | 3143 | 3306 | 18.977959 | 95 |
hcv therapy | 1373 | 1421 | 18.977522 | 97 |
end results database | 2338 | 2485 | 18.977348 | 94 |
breast cancer mcf-7 | 2195 | 2333 | 18.977290 | 94 |
national cancer data base | 1266 | 1298 | 18.977213 | 98 |
direct-acting antivirals | 3189 | 3353 | 18.976976 | 95 |
national comprehensive cancer network | 3878 | 4013 | 18.976868 | 97 |
chronic thromboembolic pulmonary hypertension (cteph) | 1540 | 1612 | 18.976807 | 96 |
milan criteria | 1609 | 1690 | 18.976745 | 95 |
crc screening | 3214 | 3378 | 18.976726 | 95 |
l858r | 2307 | 2453 | 18.976726 | 94 |
prostate cancer diagnosis | 1881 | 1993 | 18.976620 | 94 |
hiv/sti | 1494 | 1560 | 18.976568 | 96 |
chb patients | 2869 | 3035 | 18.976375 | 95 |
anticancer efficacy | 3155 | 3321 | 18.976098 | 95 |
childhood cancer survivor | 2764 | 2929 | 18.976018 | 94 |
hiv acquisition | 2348 | 2498 | 18.975495 | 94 |
prevention of mother-to-child transmission | 1977 | 2100 | 18.975024 | 94 |
children with type 1 diabetes | 2625 | 2788 | 18.974966 | 94 |
significant prostate cancer | 1668 | 1758 | 18.974965 | 95 |
cancer targeted | 2467 | 2624 | 18.974845 | 94 |
latent tuberculosis infection | 3184 | 3352 | 18.974688 | 95 |
hiv prevention intervention | 1802 | 1908 | 18.974449 | 94 |
kaposi's sarcoma-associated herpesvirus (kshv) | 1323 | 1366 | 18.974288 | 97 |
locally advanced rectal cancer | 3462 | 3624 | 18.974066 | 96 |
genotype 1b | 2162 | 2302 | 18.973716 | 94 |
stroke registry | 2004 | 2131 | 18.973666 | 94 |
sentinel nodes | 2037 | 2167 | 18.973601 | 94 |
peritoneal cancer | 2010 | 2138 | 18.973264 | 94 |
metastatic castration-resistant | 3419 | 3584 | 18.973232 | 95 |
escherichia coli (stec) | 2331 | 2483 | 18.973218 | 94 |
her2 expression | 2066 | 2199 | 18.973163 | 94 |
transarterial chemoembolization (tace) | 2411 | 2568 | 18.972821 | 94 |
hiv-exposed | 1766 | 1870 | 18.972479 | 94 |
improving global outcomes | 2092 | 2228 | 18.972460 | 94 |
hiv-1 subtypes | 1406 | 1463 | 18.972358 | 96 |
lymph node ratio | 1546 | 1623 | 18.972087 | 95 |
asthma diagnosis | 1744 | 1846 | 18.971953 | 94 |
castration-resistant prostate cancer (crpc) | 2451 | 2612 | 18.971375 | 94 |
hiv-1 integrase | 1825 | 1937 | 18.971090 | 94 |
brca1/2 mutation | 2130 | 2271 | 18.970856 | 94 |
end-stage kidney disease (eskd) | 1566 | 1647 | 18.970626 | 95 |
obstructive cad | 1536 | 1613 | 18.970561 | 95 |
prostate cancer (pc) | 3303 | 3477 | 18.969984 | 95 |
b-cell lymphoma-2 | 1677 | 1773 | 18.969880 | 95 |
folfiri | 2956 | 3134 | 18.969281 | 94 |
diabetic kidney disease (dkd) | 1993 | 2124 | 18.969267 | 94 |
mucosa-associated lymphoid tissue lymphoma | 1571 | 1654 | 18.969158 | 95 |
cancer pain relief | 2164 | 2310 | 18.968942 | 94 |
chronic hepatitis c patients | 2257 | 2410 | 18.968774 | 94 |
colorectal cancer risk | 2801 | 2978 | 18.968647 | 94 |
combination antiretroviral therapy (cart) | 1810 | 1923 | 18.968546 | 94 |
human prostate cancer cells | 2923 | 3102 | 18.968499 | 94 |
pathological complete response (pcr) | 1893 | 2015 | 18.968489 | 94 |
tki treatment | 1674 | 1771 | 18.968459 | 95 |
ln metastasis | 2703 | 2878 | 18.968419 | 94 |
pm2.5 exposure | 2904 | 3083 | 18.968378 | 94 |
incident stroke | 1358 | 1411 | 18.968317 | 96 |
cryptogenic stroke | 1880 | 2001 | 18.968158 | 94 |
recurrent ovarian cancer | 2011 | 2145 | 18.968107 | 94 |
crc cell lines | 2461 | 2627 | 18.968098 | 94 |
sentinel lymph node (sln) | 3107 | 3287 | 18.968092 | 95 |
sustained viral response | 1389 | 1447 | 18.967979 | 96 |
hodgkin lymphoma (hl) | 2301 | 2458 | 18.967949 | 94 |
adjuvant chemoradiation | 2842 | 3021 | 18.967837 | 94 |
tki therapy | 1607 | 1696 | 18.967834 | 95 |
hormone receptor-positive | 3088 | 3269 | 18.967551 | 94 |
hbv dna levels | 1691 | 1791 | 18.967545 | 94 |
breast cancer mcf-7 cell | 1649 | 1744 | 18.967249 | 95 |
new-onset diabetes | 2030 | 2167 | 18.967019 | 94 |
incidence of type 2 diabetes | 1719 | 1823 | 18.966966 | 94 |
anti-obesity effect | 2097 | 2240 | 18.966931 | 94 |
nonsmall cell lung cancer (nsclc) | 1464 | 1534 | 18.966925 | 95 |
peg-ifn | 2605 | 2779 | 18.966905 | 94 |
chronic hepatitis c virus (hcv) | 3381 | 3559 | 18.966687 | 95 |
p[8] | 1249 | 1286 | 18.966578 | 97 |
programmed death-ligand 1 (pd-l1) | 2057 | 2197 | 18.966531 | 94 |
chronic thromboembolic pulmonary hypertension | 2518 | 2689 | 18.966467 | 94 |
metastatic rcc | 2175 | 2325 | 18.966384 | 94 |
urothelial carcinoma (uc) | 1285 | 1328 | 18.966365 | 97 |
human colorectal cancer cell | 2214 | 2367 | 18.966349 | 94 |
resistant breast cancer | 2186 | 2337 | 18.966262 | 94 |
cancer-related genes | 2525 | 2697 | 18.965983 | 94 |
h5n1 virus | 2317 | 2478 | 18.965674 | 94 |
hiv coinfection | 1591 | 1680 | 18.965533 | 95 |
gastric cancer cell lines | 2653 | 2831 | 18.965347 | 94 |
thrombolysis in cerebral infarction | 1219 | 1252 | 18.965240 | 97 |
atherosclerotic cardiovascular disease (ascvd) | 1976 | 2110 | 18.965190 | 94 |
androgen deprivation therapy (adt) | 2986 | 3171 | 18.965078 | 94 |
flt3-itd | 1866 | 1989 | 18.964909 | 94 |
type 2 diabetes mellitus (dm) | 2632 | 2810 | 18.964844 | 94 |
virologic failure | 1639 | 1735 | 18.964838 | 94 |
cancer xenograft model | 1392 | 1453 | 18.964823 | 96 |
apoptosis of cancer cells | 1425 | 1491 | 18.964822 | 96 |
2009 h1n1 | 1773 | 1886 | 18.964433 | 94 |
substance use disorder (sud) | 2249 | 2407 | 18.964409 | 93 |
asthma model | 2038 | 2179 | 18.964205 | 94 |
large vessel occlusion | 2921 | 3107 | 18.964113 | 94 |
anti-cancer properties | 2069 | 2213 | 18.964039 | 93 |
brca2 mutation | 2996 | 3183 | 18.963888 | 94 |
advanced non-small-cell lung cancer (nsclc) | 1565 | 1652 | 18.963850 | 95 |
hnscc patients | 2443 | 2614 | 18.963780 | 93 |
progression of chronic kidney disease | 1801 | 1918 | 18.963713 | 94 |
integrase inhibitor | 2420 | 2590 | 18.963586 | 93 |
chronic thromboembolic pulmonary | 2537 | 2713 | 18.963540 | 94 |
plasma hiv rna | 1278 | 1322 | 18.963491 | 97 |
her2-positive breast cancer | 2898 | 3085 | 18.963303 | 94 |
sentinel node biopsy | 3250 | 3437 | 18.963165 | 95 |
stroke subtypes | 1895 | 2023 | 18.963161 | 94 |
her2-negative | 3168 | 3356 | 18.963138 | 94 |
endometrial cancer (ec) | 2464 | 2637 | 18.963137 | 93 |
ln metastases | 1496 | 1574 | 18.963010 | 95 |
head-and-neck cancer | 1325 | 1377 | 18.962949 | 96 |
diabetes-related complication | 1703 | 1809 | 18.962945 | 94 |
stroke recurrence | 2144 | 2296 | 18.962732 | 93 |
her2 positive | 1826 | 1947 | 18.962619 | 94 |
diabetes self-management | 3170 | 3359 | 18.962546 | 94 |
muscle invasive bladder cancer | 2676 | 2859 | 18.962495 | 94 |
hepatitis c virus genotype | 1897 | 2026 | 18.962439 | 94 |
t790m | 2812 | 2999 | 18.962330 | 94 |
human neuroblastoma sh-sy5y | 1512 | 1593 | 18.962215 | 95 |
cancer cell survival | 2654 | 2837 | 18.961981 | 94 |
cancer-specific survival (css) | 3176 | 3366 | 18.961935 | 94 |
targeted cancer therapy | 2119 | 2270 | 18.961828 | 93 |
anticancer drug delivery | 1663 | 1765 | 18.961821 | 94 |
brca1 mutation | 2154 | 2308 | 18.961770 | 93 |
antiretroviral treatment (art) | 2175 | 2331 | 18.961529 | 93 |
women living with hiv | 2369 | 2539 | 18.961354 | 93 |
obesity status | 1771 | 1887 | 18.961267 | 94 |
h5n1 influenza | 1489 | 1568 | 18.960679 | 95 |
biochemical recurrence (bcr) | 1388 | 1452 | 18.960341 | 96 |
non-small cell lung cancer cells | 2050 | 2197 | 18.960021 | 93 |
alk-positive | 1679 | 1785 | 18.959827 | 94 |
co-infected patients | 1905 | 2038 | 18.959563 | 93 |
upper tract urothelial carcinoma | 1462 | 1538 | 18.959511 | 95 |
international study of asthma and allergies in childhood | 1132 | 1154 | 18.959481 | 98 |
metabolic tumor volume | 1558 | 1648 | 18.959462 | 95 |
cancer detection rate | 2179 | 2338 | 18.959368 | 93 |
diabetes-related complications | 1630 | 1730 | 18.959357 | 94 |
american joint committee on cancer (ajcc) | 2107 | 2260 | 18.959308 | 93 |
her2 overexpression | 1421 | 1491 | 18.959249 | 95 |
diabetes model | 1762 | 1879 | 18.959226 | 94 |
nucleos(t)ide analog | 1786 | 1906 | 18.959116 | 94 |
transcatheter arterial chemoembolization (tace) | 1873 | 2003 | 18.959115 | 94 |
cancer inflammation | 1728 | 1841 | 18.959040 | 94 |
pathologic complete response | 3332 | 3525 | 18.958991 | 95 |
hcc treatment | 1964 | 2104 | 18.958821 | 93 |
multidrug-resistant tuberculosis (mdr-tb) | 1478 | 1557 | 18.958796 | 95 |
obesity type | 2300 | 2469 | 18.958670 | 93 |
prostate cancer treatment | 2941 | 3136 | 18.958669 | 94 |
non-muscle-invasive bladder cancer | 1392 | 1458 | 18.958641 | 95 |
b-cell non-hodgkin lymphoma | 1538 | 1626 | 18.958525 | 95 |
xenograft tumor growth | 1509 | 1593 | 18.958302 | 95 |
chronic hepatitis b patients | 2592 | 2778 | 18.958262 | 93 |
visceral obesity | 2687 | 2877 | 18.958052 | 93 |
people living with hiv (plwh) | 2171 | 2331 | 18.958034 | 93 |
suicide gene | 2460 | 2640 | 18.957922 | 93 |
hcc development | 2912 | 3108 | 18.957798 | 94 |
breast cancer model | 2595 | 2782 | 18.957662 | 93 |
treatment of hepatitis c | 2050 | 2200 | 18.957465 | 93 |
egfr tyrosine kinase inhibitor | 3094 | 3292 | 18.957439 | 94 |
hnscc cells | 1293 | 1344 | 18.957422 | 96 |
eastern cooperative oncology group performance status | 3208 | 3406 | 18.957155 | 94 |
sh-sy5y neuroblastoma | 1886 | 2020 | 18.956752 | 93 |
cancer history | 2094 | 2249 | 18.956678 | 93 |
oscc cells | 1685 | 1795 | 18.956524 | 94 |
stroke subtype | 2970 | 3169 | 18.956415 | 94 |
brca mutation | 2700 | 2893 | 18.956350 | 93 |
resistant cancer cells | 2025 | 2174 | 18.956271 | 93 |
prostate-specific membrane | 3065 | 3265 | 18.956220 | 94 |
prostate-specific membrane antigen | 3050 | 3250 | 18.956185 | 94 |
breast cancer mcf-7 cells | 1391 | 1459 | 18.955979 | 95 |
svr12 | 1268 | 1316 | 18.955843 | 96 |
brca2 mutations | 1679 | 1789 | 18.955720 | 94 |
tnbc cells | 2372 | 2550 | 18.955522 | 93 |
anticancer mechanism | 1554 | 1647 | 18.955518 | 94 |
nab-paclitaxel | 1919 | 2058 | 18.955485 | 93 |
overweight, obesity | 1779 | 1902 | 18.955389 | 94 |
hba 1c | 2144 | 2305 | 18.955373 | 93 |
metastatic setting | 1993 | 2140 | 18.955253 | 93 |
survivorship care | 1706 | 1820 | 18.955229 | 94 |
hiv rna level | 1253 | 1299 | 18.955107 | 96 |
cardiovascular disease (cvd) risk factors | 1405 | 1476 | 18.955010 | 95 |
allergy, asthma | 4618 | 4736 | 18.954968 | 98 |
anticancer therapeutic | 2791 | 2989 | 18.954904 | 93 |
ischemic stroke (is) | 2439 | 2622 | 18.954882 | 93 |
human neuroblastoma sh-sy5y cell | 1404 | 1475 | 18.954817 | 95 |
diabetes technology | 1695 | 1808 | 18.954796 | 94 |
nsclc cell lines | 2714 | 2910 | 18.954677 | 93 |
effusion lymphoma | 1474 | 1556 | 18.954607 | 95 |
chronic kidney disease epidemiology collaboration | 1268 | 1317 | 18.954489 | 96 |
lung cancer surgery | 1899 | 2037 | 18.954406 | 93 |
denv-2 | 1453 | 1532 | 18.954369 | 95 |
incident cvd | 1279 | 1330 | 18.954299 | 96 |
cvd event | 3627 | 3820 | 18.954286 | 95 |
acute ischaemic stroke | 2405 | 2587 | 18.954110 | 93 |
prevalence of type 2 diabetes | 2454 | 2639 | 18.954065 | 93 |
cteph | 1784 | 1909 | 18.954042 | 93 |
oligometastatic | 2283 | 2457 | 18.953888 | 93 |
virological failure | 2123 | 2284 | 18.953864 | 93 |
breast cancer susceptibility | 2629 | 2823 | 18.953859 | 93 |
t790m mutation | 1418 | 1492 | 18.953849 | 95 |
glucagon-like peptide-1 receptor agonist | 2253 | 2425 | 18.953688 | 93 |
large b-cell lymphomas | 1514 | 1603 | 18.953459 | 94 |
hepatitis c treatment | 1329 | 1389 | 18.953433 | 96 |
pca cells | 2566 | 2758 | 18.953292 | 93 |
disease control rate (dcr) | 2115 | 2276 | 18.953273 | 93 |
second-line chemotherapy | 2613 | 2808 | 18.952710 | 93 |
linkage to care | 1635 | 1742 | 18.952695 | 94 |
a549 lung cancer cells | 1242 | 1288 | 18.952514 | 96 |
controlled asthma | 3334 | 3539 | 18.952297 | 94 |
prostate cancer progression | 3111 | 3318 | 18.952135 | 94 |
locally advanced cervical cancer | 1768 | 1893 | 18.952125 | 93 |
nucleos(t)ide | 2132 | 2296 | 18.952060 | 93 |
tumor necrosis factor-related apoptosis-inducing ligand (trail) | 1789 | 1917 | 18.951738 | 93 |
persistent asthma | 3700 | 3895 | 18.951687 | 95 |
symptomatic intracranial hemorrhage | 1578 | 1678 | 18.951621 | 94 |
men living with hiv | 2915 | 3121 | 18.951603 | 93 |
hiv stigma | 1418 | 1494 | 18.951434 | 95 |
concurrent chemoradiotherapy (ccrt) | 1360 | 1427 | 18.951009 | 95 |
advanced hcc | 3355 | 3562 | 18.950991 | 94 |
international diabetes federation | 2811 | 3016 | 18.950751 | 93 |
b-cell lymphoma 2 | 2713 | 2915 | 18.950687 | 93 |
stroke therapy | 2228 | 2402 | 18.950581 | 93 |
pancreatic cancer cell lines | 2787 | 2992 | 18.950312 | 93 |
tumor necrosis factor-related apoptosis-inducing ligand | 2467 | 2658 | 18.950288 | 93 |
cancer-related gene | 2966 | 3175 | 18.950260 | 93 |
curative-intent | 1698 | 1816 | 18.950127 | 94 |
microvascular invasion | 1675 | 1790 | 18.950047 | 94 |
response to neoadjuvant chemotherapy | 1973 | 2124 | 18.949941 | 93 |
breast cancer resistance protein (bcrp) | 1186 | 1224 | 18.949937 | 97 |
cancer stem cell (csc) | 1891 | 2033 | 18.949935 | 93 |
carcinoma, hepatocellular | 1214 | 1257 | 18.949885 | 97 |
mpmri | 1873 | 2013 | 18.949874 | 93 |
nonsmall cell lung cancer | 2925 | 3134 | 18.949854 | 93 |
bladder cancer (bc) | 1934 | 2081 | 18.949761 | 93 |
diffuse large b cell lymphoma | 3232 | 3443 | 18.949612 | 94 |
ventilator-associated pneumonia (vap) | 2944 | 3154 | 18.949439 | 93 |
hormone-refractory | 1938 | 2086 | 18.949260 | 93 |
ckd progression | 1917 | 2063 | 18.948968 | 93 |
hepatocellular carcinoma (hcc) cells | 1356 | 1424 | 18.948921 | 95 |
gemcitabine (gem) | 1474 | 1561 | 18.948799 | 94 |
denv infection | 1600 | 1706 | 18.948551 | 94 |
cancer mechanism | 2792 | 3000 | 18.948474 | 93 |
atherosclerosis cardiovascular disease | 2690 | 2895 | 18.948127 | 93 |
persons living with hiv | 2263 | 2443 | 18.948077 | 93 |
hmlh1 | 1728 | 1852 | 18.948077 | 93 |
ncdb | 1638 | 1750 | 18.947890 | 94 |
preoperative chemoradiotherapy | 1638 | 1750 | 18.947890 | 94 |
neoplasm staging | 1749 | 1876 | 18.947810 | 93 |
cancer cost | 1702 | 1823 | 18.947636 | 93 |
incident type 2 diabetes | 1166 | 1202 | 18.947615 | 97 |
testis antigen | 1636 | 1748 | 18.947597 | 94 |
b16f10 melanoma | 1826 | 1963 | 18.947472 | 93 |
seasonal influenza vaccine | 1552 | 1652 | 18.947471 | 94 |
prostate cancer detection | 1937 | 2087 | 18.947376 | 93 |
hiv co-infection | 2134 | 2304 | 18.947304 | 93 |
merkel cell carcinoma (mcc) | 1523 | 1619 | 18.947089 | 94 |
sh-sy5y neuroblastoma cell | 1751 | 1879 | 18.947082 | 93 |
brca1 or brca2 | 1646 | 1760 | 18.946969 | 94 |
primary effusion lymphoma | 1432 | 1514 | 18.946909 | 95 |
esophageal cancer (ec) | 1688 | 1808 | 18.946741 | 93 |
human colorectal cancer cells | 1400 | 1477 | 18.946714 | 95 |
neoadjuvant chemoradiotherapy | 3352 | 3567 | 18.946608 | 94 |
cardiovascular disease (cvd) risk | 3968 | 4160 | 18.946226 | 95 |
epidermal growth factor receptor tyrosine kinase inhibitor | 1578 | 1683 | 18.946197 | 94 |
pmtct | 2047 | 2210 | 18.946178 | 93 |
lung cancer treatment | 2637 | 2843 | 18.945963 | 93 |
epidermal growth factor receptor-2 | 1576 | 1681 | 18.945879 | 94 |
extrathyroidal extension | 1377 | 1451 | 18.945763 | 95 |
primary effusion | 1457 | 1544 | 18.945698 | 94 |
hiv-related stigma | 1230 | 1279 | 18.945450 | 96 |
human cervical cancer cell | 1768 | 1900 | 18.945316 | 93 |
lung cancer a549 | 1442 | 1527 | 18.945245 | 94 |
art adherence | 1864 | 2008 | 18.945209 | 93 |
gleason scores | 1749 | 1879 | 18.944865 | 93 |
internal tandem duplication | 1497 | 1591 | 18.944849 | 94 |
epidermal growth factor receptor mutation | 1325 | 1391 | 18.944840 | 95 |
influenza a(h1n1) | 1665 | 1784 | 18.944536 | 93 |
cancer theranostic | 2018 | 2180 | 18.944498 | 93 |
recurrent prostate cancer | 1461 | 1550 | 18.944101 | 94 |
classical hodgkin lymphoma | 1380 | 1456 | 18.943905 | 95 |
autoimmune hepatitis (aih) | 2275 | 2462 | 18.943412 | 92 |
human epidermal growth factor receptor-2 | 1527 | 1627 | 18.943293 | 94 |
advanced chronic kidney disease | 1462 | 1552 | 18.943121 | 94 |
time to progression (ttp) | 1655 | 1774 | 18.943094 | 93 |
cancer cell viability | 1441 | 1528 | 18.942690 | 94 |
alcohol use disorders identification test (audit) | 1164 | 1203 | 18.942672 | 97 |
highly pathogenic avian influenza virus | 1332 | 1401 | 18.942525 | 95 |
five-year overall survival | 1958 | 2116 | 18.942352 | 93 |
objective response rate (orr) | 3631 | 3847 | 18.942327 | 94 |
breast cancer subtypes | 2695 | 2909 | 18.942294 | 93 |
epithelial ovarian cancer (eoc) | 3539 | 3758 | 18.942269 | 94 |
opioid use disorder (oud) | 2090 | 2262 | 18.942221 | 92 |
trastuzumab. | 2293 | 2483 | 18.942209 | 92 |
abirateron | 2690 | 2904 | 18.942156 | 93 |
abiraterone | 2685 | 2899 | 18.942015 | 93 |
non-muscle invasive | 1795 | 1934 | 18.941907 | 93 |
total lesion glycolysis | 1375 | 1452 | 18.941635 | 95 |
5-year dfs | 1590 | 1701 | 18.941634 | 93 |
neoadjuvant chemotherapy (nact) | 1369 | 1445 | 18.941624 | 95 |
lifetime cancer risk | 2024 | 2190 | 18.941613 | 92 |
adults with diabetes | 2864 | 3085 | 18.941521 | 93 |
treatment-experienced | 1729 | 1860 | 18.941267 | 93 |
glucagon-like peptide-1 receptor agonists | 1439 | 1527 | 18.941124 | 94 |
alcohol use disorder (aud) | 2837 | 3058 | 18.941038 | 93 |
mucosa-associated lymphoid tissue (malt) lymphoma | 1426 | 1512 | 18.940981 | 94 |
diffuse large b cell | 3485 | 3708 | 18.940884 | 94 |
cancer mouse model | 1450 | 1540 | 18.940869 | 94 |
hcc progression | 2375 | 2573 | 18.940837 | 92 |
stroke centers | 1228 | 1280 | 18.940788 | 96 |
hiv viral load | 3440 | 3665 | 18.940329 | 94 |
obesity weight loss | 1602 | 1716 | 18.940323 | 93 |
receptor tyrosine kinase inhibitors | 1552 | 1659 | 18.939776 | 94 |
acute ischemic stroke (ais) | 3805 | 4019 | 18.939764 | 95 |
braf mutations | 2632 | 2847 | 18.939731 | 92 |
chronic thromboembolic | 2802 | 3024 | 18.939701 | 93 |
human hepatocellular carcinoma (hcc) | 1940 | 2099 | 18.939670 | 92 |
human prostate cancer cell line | 1839 | 1986 | 18.939597 | 93 |
programmed cell death ligand | 1939 | 2098 | 18.939569 | 92 |
advanced non-small-cell lung cancer | 3154 | 3383 | 18.939377 | 93 |
bxpc-3 | 1643 | 1764 | 18.939253 | 93 |
neoadjuvant setting | 1690 | 1818 | 18.938918 | 93 |
melanoma differentiation | 1321 | 1391 | 18.938805 | 95 |
pi-rads | 1390 | 1472 | 18.938589 | 94 |
enzalutamid | 2566 | 2780 | 18.938077 | 92 |
microsatellite stable | 1323 | 1394 | 18.937968 | 95 |
enzalutamide | 2562 | 2776 | 18.937924 | 92 |
anti-cancer activities | 1770 | 1910 | 18.937822 | 93 |
colorectal cancer cell lines | 2010 | 2179 | 18.937764 | 92 |
spoligotyping | 1483 | 1581 | 18.937755 | 94 |
type 1 diabetes mellitus (t1dm) | 4036 | 4242 | 18.937583 | 95 |
tyrosine kinase inhibitor (tki) | 3011 | 3242 | 18.937352 | 93 |
upper tract urothelial | 1636 | 1758 | 18.937157 | 93 |
tongue squamous cell carcinoma | 1691 | 1821 | 18.937041 | 93 |
protumor | 1849 | 2000 | 18.937039 | 92 |
chronic hiv | 1705 | 1837 | 18.937002 | 93 |
human hepatocellular carcinoma cells | 1460 | 1555 | 18.936924 | 94 |
targeted anticancer | 1490 | 1590 | 18.936752 | 94 |
advanced non-small cell lung cancer (nsclc) | 3630 | 3857 | 18.936689 | 94 |
chronic hepatitis c virus infection | 1919 | 2079 | 18.936601 | 92 |
common toxicity criteria | 1507 | 1610 | 18.936427 | 94 |
diabetes prevention program | 1350 | 1427 | 18.936314 | 95 |
human hepatocellular carcinoma cell | 2520 | 2734 | 18.936229 | 92 |
stable coronary artery disease (cad) | 1151 | 1192 | 18.936149 | 97 |
obesity paradox | 1332 | 1406 | 18.936144 | 95 |
stroke units | 1518 | 1623 | 18.936139 | 94 |
h7n9 | 1939 | 2102 | 18.936022 | 92 |
prostate cancer (cap) | 1177 | 1223 | 18.935994 | 96 |
prior stroke | 1575 | 1689 | 18.935980 | 93 |
pegylated interferon and ribavirin | 1198 | 1248 | 18.935879 | 96 |
stroke severity | 4244 | 4440 | 18.935628 | 96 |
cancer susceptibility gene | 2261 | 2457 | 18.935600 | 92 |
pediatric asthma | 2457 | 2668 | 18.935517 | 92 |
a(h1n1) | 2708 | 2933 | 18.935412 | 92 |
oral cancer cell | 1672 | 1801 | 18.935318 | 93 |
human neuroblastoma sh-sy5y cells | 1250 | 1310 | 18.935288 | 95 |
lymphovascular space | 1239 | 1297 | 18.935274 | 96 |
integrase inhibitors | 1532 | 1640 | 18.935256 | 93 |
cancer cell migration and invasion | 1427 | 1518 | 18.935223 | 94 |
insulin resistance obesity | 2747 | 2974 | 18.935179 | 92 |
clinical benefit rate | 1322 | 1395 | 18.935176 | 95 |
large b cell lymphoma | 3569 | 3801 | 18.935041 | 94 |
hepatitis c patients | 3285 | 3522 | 18.934798 | 93 |
sy5y neuroblastoma | 2004 | 2176 | 18.934624 | 92 |
hcv patients | 3353 | 3590 | 18.934518 | 93 |
uncomplicated malaria | 1924 | 2087 | 18.934451 | 92 |
antiretroviral regimen | 2221 | 2415 | 18.934436 | 92 |
hormone-refractory prostate cancer | 1274 | 1339 | 18.934424 | 95 |
cancer-associated fibroblasts (cafs) | 2114 | 2298 | 18.934304 | 92 |
xenograft tumor model | 2240 | 2436 | 18.934194 | 92 |
hepatitis c (hcv) | 2174 | 2364 | 18.934176 | 92 |
and type 1 diabetes | 2017 | 2191 | 18.934141 | 92 |
stage i nsclc | 1170 | 1216 | 18.934085 | 96 |
cervical cancer (cc) | 2016 | 2190 | 18.934048 | 92 |
hiv cohort | 1245 | 1305 | 18.934044 | 95 |
a/h1n1 | 1920 | 2083 | 18.934025 | 92 |
nodal staging | 1463 | 1561 | 18.934012 | 94 |
nk/t-cell lymphoma | 1283 | 1350 | 18.933928 | 95 |
chronic thromboemboli | 2852 | 3085 | 18.933772 | 92 |
secondary stroke | 1510 | 1616 | 18.933591 | 93 |
treatment of chronic hepatitis c | 2065 | 2245 | 18.933442 | 92 |
cancer apoptosis | 1434 | 1528 | 18.933057 | 94 |
european organization for research and treatment of cancer | 3843 | 4069 | 18.932991 | 94 |
thromboembolic pulmonary hypertension | 2575 | 2797 | 18.932930 | 92 |
anti-obesity effects | 1329 | 1405 | 18.932922 | 95 |
multikinase inhibitor | 1754 | 1897 | 18.932829 | 92 |
response evaluation criteria in solid tumors | 3783 | 4012 | 18.932816 | 94 |
folfox | 3932 | 4154 | 18.932798 | 95 |
cancer drug delivery | 3371 | 3611 | 18.932778 | 93 |
asthma quality of life | 1197 | 1249 | 18.932776 | 96 |
diabetes diagnosis | 2381 | 2591 | 18.932329 | 92 |
chronic kidney disease patients | 2906 | 3143 | 18.932287 | 92 |
nk/t-cell | 1343 | 1422 | 18.932256 | 94 |
cancer specific survival | 1478 | 1580 | 18.932241 | 94 |
cancer cell death | 3763 | 3994 | 18.932231 | 94 |
colorectal cancer cell line | 3022 | 3262 | 18.932082 | 93 |
hnscc cell lines | 1205 | 1259 | 18.932073 | 96 |
current asthma | 1932 | 2099 | 18.931743 | 92 |
hmlh | 1782 | 1930 | 18.931673 | 92 |
mcf-7 cancer cell | 1290 | 1360 | 18.931644 | 95 |
art initiation | 3883 | 4110 | 18.931580 | 94 |
hcv replication | 2191 | 2386 | 18.931482 | 92 |
esophageal cancer cell | 1795 | 1945 | 18.931428 | 92 |
influenza-like illness (ili) | 1300 | 1372 | 18.931394 | 95 |
mtb/rif | 1943 | 2112 | 18.931135 | 92 |
her2-overexpressing | 1196 | 1249 | 18.931091 | 96 |
androgen-independent prostate cancer | 1243 | 1305 | 18.930816 | 95 |
direct-acting antivirals (daas) | 1216 | 1273 | 18.930763 | 96 |
chronic kidney disease stage | 1297 | 1369 | 18.930686 | 95 |
drug use disorder | 1439 | 1536 | 18.930512 | 94 |
in vitro anticancer activity | 1599 | 1722 | 18.930284 | 93 |
muscle-invasive bladder cancer | 3993 | 4217 | 18.930269 | 95 |
hepatitis e virus (hev) | 3489 | 3732 | 18.930233 | 93 |
recurrence-free survival rate | 1950 | 2121 | 18.930107 | 92 |
colorectal carcinoma (crc) | 1712 | 1852 | 18.930012 | 92 |
severe stroke | 1813 | 1967 | 18.929911 | 92 |
tb diagnosis | 2100 | 2288 | 18.929857 | 92 |
colorectal cancer liver metastases | 1223 | 1282 | 18.929810 | 95 |
hcv coinfection | 1165 | 1213 | 18.929791 | 96 |
human lung cancer cells | 2485 | 2706 | 18.929746 | 92 |
drug-resistant cancer | 1304 | 1378 | 18.929734 | 95 |
diffuse large b cell lymphoma (dlbcl) | 1354 | 1437 | 18.929675 | 94 |
braf inhibitor | 2360 | 2572 | 18.929665 | 92 |
adults with cancer | 1751 | 1897 | 18.929512 | 92 |
direct-acting antiviral agent | 1330 | 1409 | 18.929330 | 94 |
endovascular thrombectomy | 1505 | 1614 | 18.929311 | 93 |
cancer gene expression | 2257 | 2461 | 18.929180 | 92 |
clinicopathologic factors | 2740 | 2976 | 18.929156 | 92 |
hepatitis c virus (hcv) genotype | 1231 | 1292 | 18.929121 | 95 |
atezolizumab | 2267 | 2472 | 18.929093 | 92 |
highly pathogenic avian influenza | 3550 | 3794 | 18.929041 | 94 |
brca1 and brca2 mutation | 1268 | 1336 | 18.928965 | 95 |
breast cancer stem cell | 1865 | 2027 | 18.928775 | 92 |
liver cancer cells | 3197 | 3445 | 18.928605 | 93 |
tumor cell apoptosis | 2550 | 2777 | 18.928476 | 92 |
cancer targeted therapy | 1287 | 1359 | 18.928299 | 95 |
pancreatic cancer (pc) | 2742 | 2980 | 18.927919 | 92 |
recovery after stroke | 1670 | 1806 | 18.927903 | 92 |
response evaluation criteria in solid tumor | 3917 | 4150 | 18.927880 | 94 |
cvd mortality | 2718 | 2955 | 18.927860 | 92 |
child obesity | 1558 | 1677 | 18.927699 | 93 |
chronic hepatitis c infection | 1514 | 1626 | 18.927597 | 93 |
organ-confined | 2159 | 2356 | 18.927430 | 92 |
prostate cancer screening | 2557 | 2786 | 18.927397 | 92 |
adult congenital heart disease | 1800 | 1955 | 18.927327 | 92 |
artemisinin-based combination | 1742 | 1889 | 18.927312 | 92 |
nonsmall cell lung | 3412 | 3662 | 18.927122 | 93 |
22rv1 | 1197 | 1253 | 18.927113 | 96 |
cancer registry data | 2392 | 2610 | 18.927094 | 92 |
ribavirin (rbv) | 1457 | 1560 | 18.927057 | 93 |
overall and disease-free survival | 2575 | 2806 | 18.926776 | 92 |
prostate cancer risk | 3860 | 4098 | 18.926761 | 94 |
in vitro anticancer | 2844 | 3088 | 18.926707 | 92 |
adult cancer survivors | 1053 | 1081 | 18.926699 | 97 |
clinically localized prostate cancer | 2101 | 2293 | 18.926665 | 92 |
influenza a (h1n1) | 2569 | 2800 | 18.926528 | 92 |
circumferential resection margin | 1221 | 1282 | 18.926518 | 95 |
melanoma progression | 2035 | 2220 | 18.926509 | 92 |
subtypes of breast cancer | 1743 | 1891 | 18.926475 | 92 |
pulmonary tuberculosis (ptb) | 1687 | 1827 | 18.926396 | 92 |
uterine cervical neoplasm | 1714 | 1858 | 18.926332 | 92 |
nnrtis | 2086 | 2277 | 18.926174 | 92 |
advanced hepatocellular carcinoma | 3404 | 3656 | 18.926092 | 93 |
hereditary breast and ovarian cancer | 1417 | 1514 | 18.926060 | 94 |
mda-mb-468 | 2030 | 2215 | 18.926033 | 92 |
thyroid cancer cell | 1995 | 2176 | 18.926020 | 92 |
diffuse large b-cell lymphomas | 1283 | 1356 | 18.926016 | 95 |
asthma children | 2836 | 3081 | 18.925897 | 92 |
children with obesity | 1365 | 1453 | 18.925889 | 94 |
human gastric cancer cells | 1636 | 1769 | 18.925742 | 92 |
pcr rate | 1497 | 1608 | 18.925576 | 93 |
egfr-mutated | 1308 | 1386 | 18.925504 | 94 |
circulating tumor dna (ctdna) | 2007 | 2190 | 18.925500 | 92 |
platinum-resistant | 1544 | 1663 | 18.925252 | 93 |
hev infection | 2057 | 2246 | 18.925211 | 92 |
cancer quality of life | 4373 | 4583 | 18.924948 | 95 |
human pancreatic cancer cells | 1481 | 1590 | 18.924812 | 93 |
chronic kidney disease patient | 3057 | 3310 | 18.924760 | 92 |
stroke event | 2008 | 2192 | 18.924746 | 92 |
peginterferon | 2722 | 2964 | 18.924728 | 92 |
urinary bladder neoplasm | 1854 | 2019 | 18.924718 | 92 |
active surveillance (as) | 1137 | 1183 | 18.924716 | 96 |
breast cancer surgery | 3003 | 3255 | 18.924685 | 92 |
combination antiretroviral therapy | 3867 | 4109 | 18.924667 | 94 |
hbeag-negative | 1597 | 1725 | 18.924659 | 93 |
clinicopathologic factor | 2783 | 3028 | 18.924566 | 92 |
du145 cells | 1708 | 1853 | 18.924477 | 92 |
pc3 cells | 2553 | 2786 | 18.924477 | 92 |
reproductive healthcare | 2005 | 2189 | 18.924449 | 92 |
obesity and metabolic syndrome | 2075 | 2267 | 18.924365 | 92 |
middle east respiratory syndrome coronavirus | 1937 | 2113 | 18.924324 | 92 |
du145 cell | 1889 | 2059 | 18.924298 | 92 |
vitro anticancer activity | 1741 | 1891 | 18.924250 | 92 |
xenograft mice | 1588 | 1715 | 18.924215 | 93 |
axillary lymph node dissection (alnd) | 1346 | 1432 | 18.924134 | 94 |
clinically significant prostate cancer | 1264 | 1335 | 18.923969 | 95 |
type 2 diabetes (t2dm) | 4072 | 4305 | 18.923926 | 95 |
obesity and insulin resistance | 3638 | 3890 | 18.923785 | 94 |
acute stroke treatment | 1195 | 1253 | 18.923743 | 95 |
sh-sy5y neuroblastoma cells | 1504 | 1618 | 18.923513 | 93 |
panitumumab | 1866 | 2034 | 18.923412 | 92 |
lung cancer (lc) | 1533 | 1652 | 18.923285 | 93 |
metastasis prognosis | 1934 | 2111 | 18.923116 | 92 |
asthma exacerbations | 4136 | 4367 | 18.923060 | 95 |
ascvd | 2614 | 2853 | 18.922923 | 92 |
anti-cancer effects | 3731 | 3982 | 18.922859 | 94 |
high-grade serous | 3145 | 3403 | 18.922639 | 92 |
tobacco dependence | 2138 | 2339 | 18.922511 | 91 |
cancer survivorship | 3409 | 3668 | 18.922304 | 93 |
progression-free survival rate | 2116 | 2315 | 18.922256 | 91 |
baseline cd4 | 2079 | 2274 | 18.922250 | 91 |
latent tb | 2345 | 2566 | 18.922110 | 91 |
international prognostic index (ipi) | 1143 | 1192 | 18.922025 | 96 |
anticancer therapeutics | 1562 | 1687 | 18.921899 | 93 |
post-stroke patient | 1773 | 1930 | 18.921880 | 92 |
clinicopathologic parameter | 2365 | 2588 | 18.921863 | 91 |
orthotopic xenograft | 1805 | 1967 | 18.921374 | 92 |
sorafenib treatment | 1171 | 1226 | 18.921340 | 96 |
programmed cell death protein 1 | 2458 | 2689 | 18.921329 | 91 |
hcc cell lines | 3993 | 4236 | 18.921286 | 94 |
urinary bladder neoplasms | 1726 | 1877 | 18.921155 | 92 |
stroke, myocardial infarction | 2131 | 2333 | 18.921116 | 91 |
tyrosine kinase inhibitors (tki) | 1360 | 1451 | 18.921068 | 94 |
cancer cell cycle | 2111 | 2311 | 18.921009 | 91 |
hereditary breast | 3335 | 3597 | 18.920910 | 93 |
progression-free and overall survival | 2397 | 2624 | 18.920839 | 91 |
lymphovascular invasion (lvi) | 1099 | 1140 | 18.920810 | 96 |
imaging prostate cancer | 1164 | 1218 | 18.920791 | 96 |
substance use problem | 1555 | 1680 | 18.920667 | 93 |
lenvatinib | 1702 | 1850 | 18.920621 | 92 |
clinicopathologic parameters | 2344 | 2567 | 18.920568 | 91 |
urothelial carcinoma of the bladder | 1245 | 1315 | 18.920467 | 95 |
stroke risk factors | 2077 | 2274 | 18.920418 | 91 |
cancer theranostics | 1667 | 1810 | 18.920346 | 92 |
acute myeloid leukemia patient | 1435 | 1540 | 18.920313 | 93 |
androgen-deprivation | 1306 | 1388 | 18.919871 | 94 |
post-stroke patients | 1717 | 1868 | 18.919855 | 92 |
obesity risk | 3762 | 4018 | 18.919848 | 94 |
liver cancer cell line | 1427 | 1531 | 18.919838 | 93 |
mother-to-child transmission of hiv | 1593 | 1725 | 18.919755 | 92 |
first-line setting | 1237 | 1306 | 18.919738 | 95 |
metastatic non-small cell lung cancer | 1489 | 1604 | 18.919542 | 93 |
invasive coronary angiography | 2261 | 2478 | 18.919506 | 91 |
hiv antiretroviral therapy | 1070 | 1106 | 18.919417 | 97 |
lymph node metastasis (lnm) | 1741 | 1896 | 18.919387 | 92 |
insulin glargine | 2360 | 2586 | 18.919355 | 91 |
anti-hev | 1476 | 1589 | 18.919287 | 93 |
cancer disparities | 1341 | 1430 | 18.919231 | 94 |
ear cancer | 1706 | 1856 | 18.919229 | 92 |
neoadjuvant chemotherapy. | 3487 | 3751 | 18.919178 | 93 |
clear cell renal cell carcinoma (ccrcc) | 2994 | 3255 | 18.919176 | 92 |
detectable viral load | 1930 | 2111 | 18.919146 | 91 |
r-chop | 2618 | 2863 | 18.919054 | 91 |
asthma care | 1945 | 2128 | 18.919050 | 91 |
insulin glargin | 2378 | 2606 | 18.918990 | 91 |
lung cancer prognosis | 2044 | 2239 | 18.918974 | 91 |
anti-cancer therapy | 2856 | 3113 | 18.918874 | 92 |
immunosuppressive tumor microenvironment | 1503 | 1621 | 18.918844 | 93 |
pre-exposure prophylaxis (prep) | 3104 | 3368 | 18.918830 | 92 |
stroke risk factor | 2424 | 2656 | 18.918773 | 91 |
brca1 brca2 | 1865 | 2038 | 18.918737 | 92 |
cancer gene therapy | 3308 | 3574 | 18.918733 | 93 |
uterine cervical neoplasms | 1550 | 1676 | 18.918691 | 92 |
cervical cancer cell line | 2421 | 2653 | 18.918604 | 91 |
basal-like | 3229 | 3495 | 18.918563 | 92 |
asthma guideline | 1171 | 1228 | 18.918460 | 95 |
h1n1 pandemic | 1442 | 1550 | 18.918242 | 93 |
head and neck squamous cell carcinomas | 2192 | 2404 | 18.918177 | 91 |
definitive chemoradiotherapy | 1135 | 1185 | 18.918174 | 96 |
substance use problems | 1453 | 1563 | 18.918157 | 93 |
hiv-1 entry | 1195 | 1257 | 18.918099 | 95 |
hbv genotypes | 1179 | 1238 | 18.917869 | 95 |
xenograft growth | 1533 | 1657 | 18.917792 | 93 |
programmed death-ligand 1 | 3109 | 3375 | 18.917723 | 92 |
hiv clinics | 1229 | 1298 | 18.917624 | 95 |
ovarian cancer (oc) | 2649 | 2898 | 18.917606 | 91 |
sentinel lymph nodes | 3510 | 3777 | 18.917434 | 93 |
inflammation and cancer | 2329 | 2555 | 18.917384 | 91 |
hiv risk behavior | 1969 | 2157 | 18.917300 | 91 |
advanced/metastatic | 1142 | 1194 | 18.917298 | 96 |
programmed death ligand 1 | 2035 | 2231 | 18.917260 | 91 |
hereditary breast cancer | 1506 | 1626 | 18.917178 | 93 |
egfr-mutant | 1541 | 1667 | 18.917066 | 92 |
ovarian cancer risk | 1798 | 1964 | 18.916693 | 92 |
metastatic pancreatic cancer | 1563 | 1693 | 18.916686 | 92 |
brca mutations | 1314 | 1400 | 18.916665 | 94 |
high hiv prevalence | 1423 | 1529 | 18.916644 | 93 |
antenatal care (anc) | 2020 | 2215 | 18.916610 | 91 |
k103n | 994 | 1016 | 18.916527 | 98 |
hiv drug resistance | 1456 | 1568 | 18.916453 | 93 |
substance use disorder treatment | 1144 | 1197 | 18.916418 | 96 |
long-acting reversible | 1610 | 1748 | 18.916312 | 92 |
obesity and overweight | 2198 | 2413 | 18.916305 | 91 |
hiv services | 1609 | 1747 | 18.916144 | 92 |
cervical cancer prevention | 1766 | 1928 | 18.916141 | 92 |
breslow thickness | 1491 | 1610 | 18.915417 | 93 |
raltegravir | 1875 | 2053 | 18.915416 | 91 |
ras wild-type | 1200 | 1265 | 18.915273 | 95 |
plasma viral load | 2297 | 2523 | 18.915228 | 91 |
osimertinib | 1989 | 2182 | 18.915122 | 91 |
pre-diabetes | 2421 | 2658 | 18.915019 | 91 |
non-small cell lung cancer patients | 3484 | 3756 | 18.914993 | 93 |
colorectal cancer surgery | 1665 | 1813 | 18.914974 | 92 |
recurrence survival | 1723 | 1880 | 18.914842 | 92 |
significant cancer | 1376 | 1475 | 18.914833 | 93 |
epithelial–mesenchymal transition (emt) | 2312 | 2540 | 18.914761 | 91 |
melanoma treatment | 1569 | 1702 | 18.914531 | 92 |
aml cell lines | 1326 | 1416 | 18.914453 | 94 |
hiv-1 vaccine | 1611 | 1751 | 18.914392 | 92 |
viral load (vl) | 1881 | 2061 | 18.914339 | 91 |
chemoradiation therapy | 3380 | 3654 | 18.914336 | 93 |
hiv diagnosis | 3926 | 4187 | 18.914279 | 94 |
paclitaxel and carboplatin | 1211 | 1279 | 18.914132 | 95 |
hev rna | 1107 | 1154 | 18.914121 | 96 |
rectal cancer treatment | 1433 | 1543 | 18.914044 | 93 |
influenza a virus (iav) | 2208 | 2427 | 18.913979 | 91 |
human liver cancer | 2010 | 2207 | 18.913903 | 91 |
rectal cancer resection | 1116 | 1165 | 18.913891 | 96 |
sporadic colorectal cancer | 1414 | 1521 | 18.913549 | 93 |
prostate cancer cell lines | 4375 | 4611 | 18.913481 | 95 |
serous ovarian cancer | 2455 | 2697 | 18.913380 | 91 |
pcnsl | 1980 | 2174 | 18.913309 | 91 |
breast cancer xenograft | 1369 | 1468 | 18.913255 | 93 |
human pancreatic cancer cell | 2547 | 2796 | 18.913233 | 91 |
methicillin-resistant s. aureus (mrsa) | 2827 | 3092 | 18.913140 | 91 |
hiv-1-infected patients | 2742 | 3003 | 18.913100 | 91 |
cancer stem cell marker | 1373 | 1473 | 18.912939 | 93 |
advanced rectal cancer | 4126 | 4380 | 18.912792 | 94 |
lymph node staging | 1512 | 1637 | 18.912759 | 92 |
stroke outcome | 4016 | 4276 | 18.912752 | 94 |
obesity intervention | 1176 | 1238 | 18.912727 | 95 |
retention in care | 1535 | 1664 | 18.912687 | 92 |
post stroke | 2370 | 2606 | 18.912663 | 91 |
overweight or obesity | 4023 | 4283 | 18.912588 | 94 |
triple negative breast cancer (tnbc) | 2229 | 2452 | 18.912526 | 91 |
complicated malaria | 2188 | 2407 | 18.912370 | 91 |
gleason grade | 2422 | 2663 | 18.912215 | 91 |
breast cancer recurrence | 2025 | 2226 | 18.912063 | 91 |
novel anticancer agent | 1379 | 1481 | 18.911857 | 93 |
nucleos(t)ide analogue | 1253 | 1331 | 18.911796 | 94 |
non-small cell lung cancer cell | 3014 | 3288 | 18.911774 | 92 |
avian influenza viruses | 2943 | 3215 | 18.911636 | 92 |
chemical failure | 2179 | 2398 | 18.911627 | 91 |
cannabis use disorder | 1405 | 1512 | 18.911602 | 93 |
papillary thyroid carcinoma (ptc) | 4267 | 4515 | 18.911549 | 95 |
asthma prevalence | 1774 | 1942 | 18.911532 | 91 |
radical cystectomy (rc) | 1516 | 1643 | 18.911309 | 92 |
anaplastic thyroid cancer | 1318 | 1409 | 18.911262 | 94 |
breast cancer therapy | 3140 | 3418 | 18.911142 | 92 |
ecog ps | 1265 | 1346 | 18.910934 | 94 |
triple-negative breast cancers | 1159 | 1219 | 18.910642 | 95 |
breast cancer stem cells | 1553 | 1687 | 18.910575 | 92 |
her2+ | 3392 | 3673 | 18.910560 | 92 |
kidney disease progression | 1284 | 1369 | 18.910550 | 94 |
direct acting antiviral | 1460 | 1578 | 18.910370 | 93 |
hiv knowledge | 1426 | 1538 | 18.910221 | 93 |
cancer stemness | 1504 | 1630 | 18.910108 | 92 |
platinum-sensitive | 1221 | 1294 | 18.909982 | 94 |
cause-specific survival | 2141 | 2358 | 18.909956 | 91 |
xenograft tumors | 3825 | 4099 | 18.909951 | 93 |
exon 19 deletion | 1181 | 1246 | 18.909897 | 95 |
transcatheter arterial chemoembolization | 2914 | 3188 | 18.909788 | 91 |
osteosarcoma (os) | 2965 | 3241 | 18.909681 | 91 |
human gastric cancer cell | 2961 | 3237 | 18.909600 | 91 |
dengue virus (denv) | 3760 | 4037 | 18.909520 | 93 |
kidney disease: improving global outcomes | 1199 | 1268 | 18.909398 | 95 |
checkpoint inhibition | 2370 | 2611 | 18.909021 | 91 |
stroke recovery | 2325 | 2562 | 18.908962 | 91 |
tumor xenograft model | 1933 | 2126 | 18.908944 | 91 |
mda-mb-435 | 1585 | 1726 | 18.908854 | 92 |
bcr-abl1 | 2018 | 2222 | 18.908821 | 91 |
hepatocellular carcinoma cell line | 2280 | 2513 | 18.908752 | 91 |
papillary renal cell carcinoma | 1441 | 1557 | 18.908733 | 93 |
coronary artery calcium (cac) | 1463 | 1583 | 18.908695 | 92 |
asthma risk | 1261 | 1343 | 18.908567 | 94 |
tumor-associated macrophages (tams) | 2508 | 2761 | 18.908534 | 91 |
hiv-positive men | 1364 | 1466 | 18.908438 | 93 |
entecavir | 2958 | 3236 | 18.908338 | 91 |
du-145 | 2095 | 2309 | 18.908177 | 91 |
cancer strategy | 1233 | 1310 | 18.907802 | 94 |
disease-free and overall survival | 2602 | 2863 | 18.907653 | 91 |
drug-resistant tb | 2285 | 2520 | 18.907614 | 91 |
ajcc stage | 1572 | 1712 | 18.907594 | 92 |
aggressive prostate cancer | 1227 | 1303 | 18.907525 | 94 |
panc-1 cells | 1644 | 1796 | 18.907523 | 92 |
secondary stroke prevention | 1267 | 1351 | 18.907490 | 94 |
small cell lung cancer cells | 2488 | 2741 | 18.907468 | 91 |
ns5a | 2710 | 2978 | 18.907468 | 91 |
diabetes self-care | 1365 | 1468 | 18.907445 | 93 |
cancer outcomes | 4317 | 4571 | 18.907400 | 94 |
pathological complete response | 3893 | 4170 | 18.907296 | 93 |
human non-small cell lung cancer | 1839 | 2021 | 18.907241 | 91 |
clinicopathological variables | 2637 | 2901 | 18.907186 | 91 |
oncolytic adenovirus | 1369 | 1473 | 18.907147 | 93 |
global initiative for asthma | 1071 | 1115 | 18.907138 | 96 |
androgen-deprivation therapy | 1186 | 1254 | 18.907093 | 95 |
esophageal cancer patients | 2619 | 2882 | 18.907073 | 91 |
kras mutations | 3499 | 3786 | 18.907064 | 92 |
carcinoma hepatocellular | 3251 | 3538 | 18.906974 | 92 |
cardioembolic stroke | 2024 | 2231 | 18.906925 | 91 |
clinicopathological variable | 2677 | 2944 | 18.906854 | 91 |
panc-1 cell | 1850 | 2034 | 18.906841 | 91 |
syntax score | 1621 | 1770 | 18.906742 | 92 |
non-muscle invasive bladder cancer | 1383 | 1490 | 18.906709 | 93 |
recist criteria | 1279 | 1366 | 18.906663 | 94 |
stroke care | 3790 | 4072 | 18.906619 | 93 |
xpert mtb/rif | 1620 | 1769 | 18.906572 | 92 |
incident cancer | 1572 | 1713 | 18.906530 | 92 |
scchn | 1675 | 1833 | 18.906500 | 91 |
high-risk neuroblastoma | 1258 | 1341 | 18.906451 | 94 |
hepatitis g virus | 1008 | 1039 | 18.906350 | 97 |
hbv reactivation | 1193 | 1263 | 18.906293 | 94 |
primary hcc | 1242 | 1322 | 18.906187 | 94 |
diabetes prevention | 3956 | 4233 | 18.906075 | 93 |
human cervical cancer | 3143 | 3430 | 18.906041 | 92 |
pik3ca mutation | 1922 | 2117 | 18.905902 | 91 |
people with stroke | 1177 | 1244 | 18.905895 | 95 |
metastasis-free survival | 4475 | 4721 | 18.905862 | 95 |
xpert mtb | 1670 | 1828 | 18.905698 | 91 |
egfr tyrosine kinase | 3736 | 4022 | 18.905418 | 93 |
anthracycline-based chemotherapy | 1113 | 1167 | 18.905414 | 95 |
brafv600e | 2404 | 2653 | 18.905398 | 91 |
anti-tuberculosis treatment | 1325 | 1422 | 18.905380 | 93 |
highly pathogenic avian influenza (hpai) | 1335 | 1434 | 18.905300 | 93 |
anti-pd-l1 | 2401 | 2650 | 18.905210 | 91 |
raf inhibitors | 1717 | 1883 | 18.905146 | 91 |
cancer thyroid | 2097 | 2315 | 18.905119 | 91 |
children obesity | 1318 | 1414 | 18.904924 | 93 |
nonsmall cell | 3515 | 3806 | 18.904906 | 92 |
non-small cell lung carcinoma (nsclc) | 1450 | 1571 | 18.904850 | 92 |
type 2 diabetes risk | 1247 | 1329 | 18.904850 | 94 |
psma pet | 1272 | 1359 | 18.904849 | 94 |
asthma medication | 2556 | 2818 | 18.904806 | 91 |
pneumonia severity | 1227 | 1305 | 18.904801 | 94 |
dipeptidyl peptidase-4 inhibitor | 2361 | 2607 | 18.904791 | 91 |
esat-6 | 1477 | 1603 | 18.904738 | 92 |
direct-acting antiviral agents | 1211 | 1286 | 18.904453 | 94 |
national comprehensive cancer network (nccn) | 1133 | 1192 | 18.904230 | 95 |
egfr inhibitors | 2708 | 2981 | 18.904162 | 91 |
programmed death-ligand | 3238 | 3530 | 18.904116 | 92 |
breast cancer cell proliferation | 1878 | 2069 | 18.904081 | 91 |
anticancer treatments | 1501 | 1632 | 18.903958 | 92 |
type 1 dm | 1397 | 1509 | 18.903870 | 93 |
egfr-tki | 4172 | 4443 | 18.903867 | 94 |
vascular space invasion | 1456 | 1579 | 18.903814 | 92 |
metastasectomy | 2635 | 2904 | 18.903792 | 91 |
middle east respiratory syndrome coronavirus (mers-cov) | 1407 | 1521 | 18.903727 | 93 |
cancer intervention | 1528 | 1664 | 18.903719 | 92 |
cancer aggressiveness | 1401 | 1514 | 18.903576 | 93 |
type 2 diabetic rat | 1669 | 1829 | 18.903530 | 91 |
incident cardiovascular disease | 1121 | 1178 | 18.903446 | 95 |
csc marker | 1236 | 1317 | 18.903209 | 94 |
oral cancer cells | 1231 | 1311 | 18.903188 | 94 |
hcc diagnosis | 1162 | 1228 | 18.902879 | 95 |
late toxicities | 1696 | 1861 | 18.902873 | 91 |
crizotinib | 2778 | 3057 | 18.902846 | 91 |
breast and prostate cancer | 2480 | 2739 | 18.902845 | 91 |
cancer resistance | 4144 | 4419 | 18.902763 | 94 |
b-cell lymphoma 2 (bcl-2) | 1478 | 1606 | 18.902685 | 92 |
pulmonary tuberculosis (tb) | 1701 | 1867 | 18.902673 | 91 |
quantiferon | 2175 | 2405 | 18.902658 | 90 |
cardiovascular and cerebrovascular diseases | 1528 | 1665 | 18.902627 | 92 |
oncogenic function | 2211 | 2445 | 18.902604 | 90 |
disease-specific survival rate | 1118 | 1175 | 18.902497 | 95 |
lung cancer a549 cell | 1174 | 1243 | 18.902169 | 94 |
usual interstitial pneumonia | 1755 | 1930 | 18.902143 | 91 |
adherence to antiretroviral therapy | 1368 | 1476 | 18.902042 | 93 |
rassf1 | 1869 | 2061 | 18.902040 | 91 |
diabetes mellitus type 1 | 1848 | 2037 | 18.902029 | 91 |
antiretroviral medication | 1588 | 1736 | 18.902011 | 91 |
er-positive breast cancer | 1357 | 1463 | 18.901896 | 93 |
micropapillary | 1903 | 2100 | 18.901845 | 91 |
immune-related adverse events (iraes) | 1628 | 1783 | 18.901762 | 91 |
laryngeal squamous cell carcinoma | 2495 | 2757 | 18.901602 | 90 |
advanced melanoma | 3106 | 3400 | 18.901560 | 91 |
tumor necrosis factor-related | 2947 | 3236 | 18.901495 | 91 |
the cancer genome atlas database | 1573 | 1719 | 18.901401 | 92 |
latent tb infection | 1550 | 1692 | 18.901401 | 92 |
cancer information | 1631 | 1787 | 18.901251 | 91 |
hormone receptor (hr) | 1100 | 1154 | 18.901236 | 95 |
type 1 diabetes patients | 1209 | 1286 | 18.901129 | 94 |
alcohol-dependent patients | 1427 | 1547 | 18.901080 | 92 |
advanced esophageal cancer | 1514 | 1650 | 18.900997 | 92 |
afatinib | 1813 | 1998 | 18.900992 | 91 |
relapse-free survival (rfs) | 2369 | 2621 | 18.900966 | 90 |
suicide ideation | 3372 | 3671 | 18.900911 | 92 |
m184v | 1025 | 1063 | 18.900874 | 96 |
brafv600 | 2704 | 2982 | 18.900779 | 91 |
cancer pathogenesis | 3178 | 3475 | 18.900774 | 91 |
cancer diagnoses | 3131 | 3427 | 18.900766 | 91 |
antiretroviral (arv) | 1634 | 1791 | 18.900741 | 91 |
stroke management | 1628 | 1784 | 18.900736 | 91 |
severe maternal morbidity | 1103 | 1158 | 18.900693 | 95 |
stage iiic | 1657 | 1818 | 18.900554 | 91 |
adult congenital heart | 1878 | 2073 | 18.900496 | 91 |
advanced pancreatic cancer | 3273 | 3572 | 18.900494 | 92 |
malt lymphoma | 3411 | 3711 | 18.900424 | 92 |
pdac cells | 1494 | 1627 | 18.900332 | 92 |
plhiv | 2307 | 2554 | 18.900271 | 90 |
cancer resection | 3638 | 3937 | 18.899996 | 92 |
obesity-related disease | 1293 | 1388 | 18.899900 | 93 |
cancer cell invasion | 3457 | 3758 | 18.899873 | 92 |
downstaging | 2816 | 3102 | 18.899706 | 91 |
anti-her2 | 3240 | 3540 | 18.899698 | 92 |
pc-3 cells | 3826 | 4122 | 18.899283 | 93 |
simert | 1992 | 2204 | 18.899271 | 90 |
glargine | 2980 | 3274 | 18.899263 | 91 |
castration resistant | 1346 | 1452 | 18.899262 | 93 |
pediatric acute lymphoblastic leukemia | 1212 | 1291 | 18.899231 | 94 |
immune-checkpoint | 1729 | 1903 | 18.899204 | 91 |
mouse xenograft model | 3801 | 4098 | 18.899157 | 93 |
anti-mrsa | 1216 | 1296 | 18.898996 | 94 |
laryngeal squamous cell | 2597 | 2871 | 18.898726 | 90 |
cancer development and progression | 3515 | 3818 | 18.898691 | 92 |
rectal cancer surgery | 3526 | 3829 | 18.898651 | 92 |
diabetes medications | 1106 | 1163 | 18.898642 | 95 |
brca2 gene | 2024 | 2241 | 18.898561 | 90 |
raf inhibitor | 2949 | 3243 | 18.898547 | 91 |
interferon-free | 1157 | 1225 | 18.898488 | 94 |
bovine respiratory disease | 1414 | 1534 | 18.898208 | 92 |
hiv-1 viral load | 1040 | 1083 | 18.898089 | 96 |
chronic kidney diseases | 2221 | 2462 | 18.898051 | 90 |
micrometastasis | 2654 | 2933 | 18.898044 | 90 |
lung cancer screening | 3548 | 3852 | 18.898044 | 92 |
ovarian cancer cell lines | 3312 | 3616 | 18.897996 | 92 |
alk inhibitor | 1477 | 1609 | 18.897973 | 92 |
braf v600e mutation | 1811 | 1999 | 18.897939 | 91 |
hiv-associated neurocognitive disorder | 1466 | 1596 | 18.897936 | 92 |
community-acquired pneumonia (cap) | 4496 | 4759 | 18.897927 | 94 |
carboplatin and paclitaxel | 1141 | 1206 | 18.897904 | 95 |
severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection | 2464 | 2729 | 18.897730 | 90 |
sw620 | 2428 | 2690 | 18.897638 | 90 |
cancer symptom | 1725 | 1900 | 18.897621 | 91 |
tumor apoptosis | 1299 | 1397 | 18.897595 | 93 |
hcc risk | 1390 | 1506 | 18.897502 | 92 |
interstitial lung disease (ild) | 3910 | 4207 | 18.897473 | 93 |
multidrug-resistant tuberculosis | 3478 | 3784 | 18.897228 | 92 |
glargin | 3013 | 3312 | 18.897019 | 91 |
glycated haemoglobin (hba1c) | 1844 | 2038 | 18.896951 | 90 |
lung cancer screen | 3563 | 3869 | 18.896948 | 92 |
mcf-7 breast cancer cells | 3915 | 4213 | 18.896914 | 93 |
cardiovascular and cerebrovascular disease | 1978 | 2191 | 18.896844 | 90 |
non-small cell lung cancers | 1905 | 2108 | 18.896793 | 90 |
zikv infection | 2070 | 2295 | 18.896763 | 90 |
avian influenza virus (aiv) | 1189 | 1265 | 18.896728 | 94 |
epidermal growth factor receptor (egfr) mutations | 1072 | 1123 | 18.896526 | 95 |
germline brca | 1236 | 1322 | 18.896475 | 93 |
5-year disease-free survival | 2758 | 3046 | 18.896449 | 91 |
breast cancer subtype | 3791 | 4094 | 18.896378 | 93 |
tumor-node-metastasis (tnm) | 1145 | 1212 | 18.896235 | 94 |
laboratory-confirmed influenza | 994 | 1028 | 18.896142 | 97 |
undetectable viral load | 1430 | 1555 | 18.895921 | 92 |
high-fat diet-induced obesity | 1061 | 1110 | 18.895880 | 96 |
lung cancer diagnosis | 1683 | 1853 | 18.895845 | 91 |
cardiovascular disease prevention | 2177 | 2416 | 18.895800 | 90 |
breast cancer gene | 3069 | 3372 | 18.895775 | 91 |
asthma guidelines | 1056 | 1104 | 18.895723 | 96 |
asthma control questionnaire | 966 | 994 | 18.895690 | 97 |
Download
If you want to run the full query on Scopus.com, simply click the button below. The query will be stored in your clipboard, and you can then paste it in Scopus Advanced Search.